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Seven envelope regions from two series of patient isolates have been molecularly cloned and analyzed for replication
phenotypes and immunogenicity. Growth potential was analyzed for env sequences substituted into an HIV-1-NL4-3 backbone
(NL4-3/env recombinants). Immunogenicity studies were conducted on secreted monomeric (gp120) and oligomeric (gp140)
forms of the Envs using Env-expressing plasmid DNAs for immunizations. The env regions of the patient isolates conferred
a spectrum of replication kinetics and cytotropisms on the NL4-3/env recombinants. Both patient series included non-
syncytium-inducing viruses with no ability to grow on T-cell lines, and highly syncytium inducing viruses which grew well
on T-cell lines. These differences in growth potential did not correlate with the ability of the DNA-expressed Envs to raise
antibody in rabbits. Rather, the relative immunogenicity of the Envs was patient and form specific. The Envs from patient
5 raised higher titers of antibody than the Envs from patient 6. For each primary Env, the gp120 form of the Env raised
higher titers of antibody than the gp140 form. Thus, structural features of Env that affect replication do not necessarily
affect the ability to raise antibody. q 1997 Academic Press
INTRODUCTION isolates from the symptomatic phase of the disease often
have ‘‘rapid/high’’ replication kinetics on both PBMCs and
A central problem in the development of a vaccine for T-cell lines. These viruses frequently induce syncytia.
HIV-1 has been the identification of immunogens capable
To date no studies have been done on the relative
of raising neutralizing antibody for the envelope glycopro-
immunogenicity of ‘‘slow/low’’ and ‘‘rapid/high’’ Envs. In
teins (Env) of primary isolates. The Envs of primary iso-
general, poor replicative function has correlated with
lates have marked differences in amino acid sequence
slow entry into cells and relative resistance to antibody(for compendium, see Myers et al., 1994), replication phe-
binding (Fernandez-Larsson et al., 1992; Sullivan et al.,notype (for review, see Fenyo et al., 1989), and the ability
1995). This suggests that epitopes important to the entry-to be recognized by antibody (for reviews, see Moore
mediated steps of binding and fusion may be masked inand Ho, 1995; Fenyo et al., 1996). In this manuscript, we
‘‘slow/low’’ viruses. Indeed, targets for neutralizing anti-have undertaken an initial analysis of the effect of the
body, such as the V3 loop and the CD4-binding domain,replication phenotype of an Env on the ability of that Env
can be largely hidden from cognate antibodies in ‘‘slow/to elicit antibody.
low’’ Envs (see Bou-Habib et al., 1994; Sullivan et al.,Patient isolates from different phases of HIV-1 infection
1995; Stamatos and Cheng-Mayer, 1995). This raises theexhibit stage-specific replication characteristics (Asjo et
possibility that a greater exposure of entry epitopes inal., 1986; Cheng-Mayer et al., 1988; Fenyo et al., 1988;
‘‘rapid/high’’ viruses would cause ‘‘rapid/high’’ Envs to beTersmette et al., 1988; 1989). Viruses isolated from the
better candidates for raising neutralizing antibody thanasymptomatic phase of the disease frequently exhibit
‘‘slow/low’’ Envs.‘‘slow/low,’’ non-syncytium-inducing (NSI) replication in
The ‘‘rapid/high’’ and ‘‘slow/low’’ Envs used in this studyperipheral blood mononuclear cells (PBMCs). In general,
were molecularly cloned from serial isolates recoveredthese viruses do not replicate on cell lines. By contrast,
from two HIV-1-positive Swedish homosexual men (pa-
tient 5 and patient 6) (von Gegerfelt et al., 1991). In both
1 These authors contributed equally to this work. series, the growth characteristics of the isolates changed
2 Present address: Department of Microbiology, The University of from ‘‘slow/low’’ to ‘‘rapid/high’’ as disease progressedTexas at Austin, Austin, TX 78712.
from lymphadenopathy to ARC/AIDS. Replication pheno-3 To whom correspondence and reprint requests should be ad-
dressed. types of the Envs were assessed by substituting env
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sequences in a constant HIV-1 backbone (HIV-1-NL4-3). tions, vectors, and V3 sequence for the clones used to
construct the NL4-3/env recombinants and vaccine vec-Immunogenicity was examined using DNA-based immu-
nization, a technique with the potential to raise neutraliz- tors are summarized in Fig. 2.
ing antibody for both human and simian immunodefi-
Substitution of serial env fragments into NL4-3ciency viruses (Wang et al., 1993; Lu et al., 1995, 1996;
Okuda et al., 1995). Patient env fragments from the pcRII or pSVIII vectors
Our results reveal the serial Envs conferring a spec- were substituted for the homologous NL4-3 env fragment
trum of growth characteristics on the otherwise constant by three-fragment ligation of 12.1-kb EcoRI–BamHI and
NL4-3 backbone. They also demonstrate that the replica- 0.6-kb EcoRI–KpnI fragments of pNL4-3 and the 2.1-kb
tion phenotype of an Env is not the primary determinant KpnI–BamHI patient env fragments (See Figs. 1A–1C).
of the ability of an Env to raise antibody. Recombinant clones were identified by restriction endo-
nuclease digestion and V3 sequence analysis. Due to
MATERIALS AND METHODS problems with instability, the pNL4-3/env recombinants
were grown in Stable II E. coli (Life Sciences Inc. Gaith-Plasmids
ersburg, MD) in 20-ml vol using 50-ml tubes.
pNL4-3 (Adachi et al., 1986) was obtained from the
Construction of gp120 and gp140 vaccine plasmidsNIAID AIDS Repository, (Rockville, MD); pSVIIIenv
(Helseth et al., 1990) from Dr. J. Sodroski (Harvard Medi- Vaccine plasmids expressing gp120 and gp140 forms of
cal School, Boston, MA); pJW4303, from Dr. J. I. Mullins the Envs were constructed by cloning env fragments in
(University of Washington, Seattle, WA); pWR61602 (a hu- frame with a synthetic tissue plasminogen activator-(tPA)-
man growth hormone (hGH) expressing plasmid) from leader sequence in pJW4303 (Figs. 1D and 1E). pJW4303
Dr. J. Haynes (Auragen Inc., Madison, WI); and pCRII from is an eukaryotic expression vector that uses enhancer and
Invitrogen Corp. (San Diego, CA). Plasmids were grown promoter elements, including intron A from the cytomegalo-
in the HB101 or Stable II (Life Technologies, Gaithers- virus immediate-early promoter, and polyadenylation se-
burg, MD) strains of Escherichia coli and purified using quences from the bovine growth hormone (for details, see
Qiagen columns (Chatsworth, CA). Lu et al., 1996). pJW4303 supports Env expression in the
absence of Rev (Chapman et al., 1991). A 5* sense primer
Molecular cloning of env sequences from serial (JApcr501 5*-GTCGCTCCGCTAGCTTGTGGGTCACAGTC-
patient isolates TATTATGGGTACC-3*) used an NheI site (underlined) to
clone env fragments in frame with the tPA-sequence inSerial patient isolates that had undergone limited cul-
pJW4303. For construction of gp120, a 3* antisense primerture on PBMCs were obtained for molecular cloning (von
(JApcr504: 5*-GGTCGGATCCttaCTGCACCACTCTTCTCTT-Gegerfelt et al., 1991). The env regions were molecularly
TGCC-3*) introduced a stop codon (in lowercase) at thecloned from infected peripheral blood mononuclear cell
boundary of the surface (SU) and transmembrane (TM)(PBMC) DNA using a nested PCR approach (Fig. 1). First,
subunits of Env followed by a BamHI site (underlined) fora 3283-bp fragment containing the entire env gene and
cloning into the BamHI site in pJW4303. The 3* antisenseflanking sequences was PCR amplified using sense oli-
primer used to construct gp140 forms of env (JApcr502:5*-gonucleotide 226, 5*-TAATAAGAATTCTGCAACAACTGC-
CGACGGATCCttaTGTTTATGTCAAACCAATTCCAC-3*) in-TGTTTAT-3* (nt 5737–5768 in NL4-3) and antisense oli-
troduced a stop codon immediately prior to the transmem-gonucleotide 231, 5*-CTTAAAGGTACCTGAGGTGTG-
brane domain of TM.ACTGGAAA-3* (nt 9016– 8988 in NL4-3) (Fig. 1A). After
gel purification, this fragment was further amplified using
Heteroduplex tracking assay (HTA)
sense oligonucleotide 227, 5*-CACAGTCTATTATGG-
GGTACCTGTGTGGAA-3* (nt 6328–6358) and antisense A nested PCR approach was used to amplify a 941-
bp internal V1 – V3 region of the env sequences pre-oligonucleotide 212, 5*-GCTAAGGATCCGTTCACTAAT-
CGAATG G-3* (nt 8475–8448) to generate a 2150-bp env sent in the infected PBMC DNAs used for cloning. The
first round of amplification was performed using thefragment encompassing the KpnI (nt 6343) and BamHI
sites (nt 8465) of NL4-3 (Fig. 1B). The PCR-amplified frag- GeneAmp kit (Perkin–Elmer, Foster City, CA) and pri-
mers MNA (5*-GCGAAAGAGCAGAAGACAGTGGC-3*)ments were cloned directly into the pCRII TA-cloning
vector or digested with KpnI and BamHI and substituted and MN13 (5*-CAGCTCGTCTCATTCTTTCCC-3*) to pro-
duce a 2.6-kb fragment encompassing the entire envfor homologous sequences in pSVIIIenv. V3 loop se-
quences of each cloned fragment were obtained using gene. Hot-start PCR reactions used 30 cycles (947 for 60
sec, 607 for 90 sec, and 727 for 3 min) followed by a 10-the Sequenase Version 2.0 DNA sequencing kit (United
States Biochemical, Cleveland, OH). These signature se- min final extension step at 727. Amplification products
were desalted on Sepharose G-50 spin columns (Sigmaquences were used to verify the identity of env se-
quences in subsequent cloning procedures. Designa- Biochemicals, St. Louis, MO) in TEN buffer (40 mM Tris–
AID VY 8445 / 6a2a$$$182 02-04-97 03:43:30 vira AP: Virology
271REPLICATION PHENOTYPES AND IMMUNOGENICITY OF HIV-1 ENVS
HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl) and further Western blot analyses
amplified in a second round of PCR using nested primers
Protein blots were conducted on lysates of transiently209 (5*-ACCCCAACCCACAAGAAG-3*) and 218 (5*-CCA-
transfected COS cells as previously described (Lu et al.,AGTACTATTAAACAG-3*) to produce a 941-bp product.
1996). Proteins were visualized by the Western-LightThe same conditions were used for the second round of
Chemiluminescent Detection System (Tropix, Bedford,PCR except that the hot-start was omitted and a 557
MA). HIV-Ig (1:3000 dilution) was used for the primaryannealing temperature was used. Radiolabeled probes
antibody.were made by amplifying molecularly cloned env genes
with primers 209 and 218 in the presence of 0.1 ml of 10
Antigen capture ELISA
Ci/ml [32P]dCTP (New England Nuclear, Dupont, Boston,
MA). Annealing conditions and the mobility of hetero- HIV-1 antigen was captured overnight at 47 on Easy
duplexes were as described by Delwart et al. (1994a, Wash microtiter plates (Corning, Corning, NY) coated
1994b). with a 1:5000 dilution of HIV-Ig in phosphate-buffered
saline (PBS). A standard curve was constructed in dupli-
Recovery of viral stocks and growth studies cate using a known quantity of Env protein serially diluted
in whey buffer (PBS, 4% whey powder (Davisco, Le Sueur,Viral stocks from recombinant NL4-3/env plasmids
MN), 0.05% Tween-20). This standard Env was either awere generated by transfection of Cos cells using a
baculovirus-produced IIIb-gp120 (Intracel, Cambridge,DEAE-dextran procedure (Gibbs et al., 1994). Transfec-
MA) or a vaccinia virus (vCB-14)-produced BH-8-gp140tion efficiencies were controlled by adding a hGH-ex-
(Earl et al., 1994). Captured antigen was detected usingpressing plasmid as an internal control and testing for
biotinylated HIV-Ig followed by streptavidin-linked horse-levels of hGH expression at 72 hr using an antigen cap-
radish peroxidase (Vector Laboratories Inc. Burlingame,ture ELISA (Boehringer-Mannheim, Indianapolis, IN).
CA) and TMB substrate. O.D. was measured at 450 nm.Fresh PHA-stimulated PBMCs were added to transfected
All incubations were at 237 for 60 min.COS cells at 36 hr posttransfection and the culture me-
dium was changed to RPMI 1640, 10% fetal calf serum, Env-specific antibody
and 3% IL-2 (Kabat et al., 1994). Two days later, PBMCs
were removed and cultured separately. PBMC cultures Titers of Env-specific IgG were determined by ELISA
were regularly fed and assayed for virus replication using (Robinson et al., 1990) using vaccinia-produced gp140
indirect immunofluorescence analyses and a HIV-Ig (Ab- as the solid-phase antigen. Briefly, microtiter plates were
bott, Abbott Park IL)-based antigen capture ELISA (Fer- coated with concanavalin A followed by Env antigen at
nandez-Larsson et al., 1992). Cytotropism studies were approximately 1 mg of Env per milliliter. Sample sera
carried out by cocultivating 1:1 mixtures of infected were assayed in duplicate at serial threefold dilutions
PBMCs with T-cell lines (MT-2, H9, A3.01, and CEM1174 ranging from 1:100–1:8100. A standard curve was con-
obtained from the NIAID AIDS Repository, Rockville, MD) structed using pooled sera from rabbits immunized with
in RPMI 1640 supplemented with 10% fetal calf serum a plasmid expressing HXB-2 gp120. This curve was as-
and antibiotics, and scoring virus-expressing cells using signed values that correlated with the concentration of
indirect immunofluorescence over a 2-week period. Syn- specific antibody in the pooled sera. The concentration of
cytium induction was assayed by cocultivation with MT- specific antibody in the standard was determined using
2 cells as described by Koot et al. (1992). purified rabbit IgG as a standard. Bound Env-specific IgG
was detected using biotinylated goat anti-rabbit antisera
In vitro expression of vaccine plasmids followed by streptavidin-horse radish peroxidase and
TMB substrate (all from Vector Laboratories Inc. Burlin-
Expression of plasmids was tested in transiently trans-
game, CA). The sensitivity of the assay was {0.005 mg/
fected COS cells. Transfections used 1 to 3 mg of a test
ml. Rabbit sera had backgrounds in this assay ranging
DNA, 100 ng of the hGH-expressing plasmid, 10 ml of
from 0.01 to 0.05 mg/ml.
lipofectAMINE (Life Technologies, Gaithersburg, MD)
and 5 1 105 subconfluent COS cells as described by DNA immunizations
Reiter et al. (1995). At 48 to 72 hr posttransfection, super-
nates were harvested and lysates were prepared by de- DNA immunizations were delivered to freshly shaved
abdominal skin of anesthetized female NZW rabbits withtaching cells from plates in TEN buffer, collecting the
cells by centrifugation, and resuspending the pellet in Accel electric discharge or helium pulse gene guns (Aur-
agen Inc., Middleton). DNA was precipitated onto 0.9510 mM Tris–HCl, pH 7.5, 1% Triton X-100, and 1 mM
phenylmethylsulfonylfluoride. Lysates were clarified by or 1- to 3-mm gold beads using spermidine in the pres-
ence of Ca2/ (Eisenbraun et al., 1993). Over the 2-yearmicrocentrifugation at 12,000 rpm for 60 min at 47. Anti-
gen capture ELISAs were used to determine the concen- course of these experiments various conditions and
schedules were used for immunizations. Immunizationstrations of Env (see below) and hGH.
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FIG. 1. Cloning and expression of patient Envs. A–C depict positions of primers and restriction endonuclease sites used in the PCR amplification
and subcloning of primary env fragments. D and E depict the structure and junctions of gp120 and gp140 env inserts in the pJW4303 vaccine
expression vector. For more detail, see Materials and Methods.
with the electric discharge gun included 6 shots of 0.8 ras (Figs. 1A–1C). Chimeras were constructed from
patient 5 isolates taken at times A, B, and C (designatedmg of gold with 7.2 mg of DNA, and 3 shots of 0.8 mg
of gold with 2 mg of DNA. The amount of DNA per bead NL4-3/5A, NL4-3/5B, and NL4-3/5C); and from patient 6
isolates taken at times A, B, C, and D (designated NL4-was reduced as studies revealed that levels of ⁄0.02
mg of DNA per milligram of gold did not increase the 3/6A, NL4-3/6B, NL4-3/6C, and NL4-3/6D) (von Gegerfelt
et al., 1991). Figure 2 summarizes the cloning vectorsefficiency of immunization (Pertmer et al., 1995). The
switch from the electric discharge gun to the helium and signature V3 loop sequences for each of these envs.
Hetroduplex tracking analyses revealed that each ofpulse gun was made when the helium gun became
available. Immunizations with the helium pulse gun in- the molecularly cloned envs represented the predomi-
nant env in the infected culture from which it had beencluded 6, 10, 36, and 40 shots of 0.5 mg of gold loaded
with 1.25 mg of DNA. The large number of shots with the cloned (Fig. 3 and data not shown). This was shown by
the presence of limited or undetectable heteroduplexeshelium pulse gun were used for the final DNA boosts in
all groups. for envs hybridized with sequences from the culture from
which they had been cloned (Fig. 3, lanes 1, 5, 9, 12).
The 6B env clone had V3 loop sequence with featuresRESULTS
of both the 5 and 6 series (Fig. 2). Hetroduplex tracking
Cloning and construction of NL4-3/env recombinants
analysis of this env confirmed that the 6B env belonged
for two series of patient isolates
to the patient 6 series (Fig. 3, lanes 10–16). This was
evidenced by heteroduplexes formed with DNA from pa-Env regions from two series of Swedish patient iso-
lates were PCR amplified from DNA isolated from in- tient 6 cultures having greater complementarity (migrat-
ing more rapidly) than hetroduplexes with DNA from pa-fected PBMC and substituted into a replication-compe-
tent HIV-1-NL4-3 backbone to produce NL4-3/env chime- tient 5 cultures.
FIG. 2. Designations, cloning vectors, and signature sequence data for the molecularly cloned Envs. The cysteines bounding the V3 loop are
boxed.
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env recombinants (Table 1). NL4-3/5B and NL4-3/5C ex-
hibited the most restricted growth, barely replicating on
PBMCs. NL4-3/6A had an intermediate replication phe-
notype, replicating well on PBMCs but poorly on T-cell
lines. The remaining recombinants had high replication
kinetics, yet distinctive tropisms for the four tested T-cell
lines. The NL4-3 parent exhibited the best replication
kinetics, replicating well on PBMCs as well as all tested
T-cell lines.
The NL4-3/Env recombinants also differed in their abil-
ities to induce syncytia in MT-2 cells (Table 1). The four
recombinants with high replication kinetics and broad
cytotropisms were syncytium-inducing (SI). The two re-
combinants with low replication kinetics, as well as the
one with an intermediate replication phenotype (NL4-3/
6A), did not induce syncytia.
Expression and immunogenicity of the gp120 and
gp140 vaccine plasmidsFIG. 3. Use of heteroduplex tracking analyses to establish the rela-
tionship of the molecularly cloned Envs to the envelope sequences A representative group of Envs were selected for im-
present in infected PBMCs. The PBMC DNAs and Env clones used in
munogenicity studies. These were subcloned into thethe analysis are indicated at the top of the gel. The positions of single-
pJW4303 vaccine vector in gp120 and gp140 forms (seestranded DNA and homoduplexes are on the right side. The hetero-
duplexes run between the single-stranded DNA and the homoduplexes. Figs. 1D and 1E). Western blot analyses revealed that
each of these vaccine subclones expressed the antici-
pated form of Env in transiently transfected COS cells
Effects of env sequences from the patient isolates on
(Fig. 4 and data not shown). The gp140 form underwent
the growth characteristics of pNL4-3
partial proteolytic cleavage at the SU/TM boundary, as
evidenced by a gp140 form with slightly more rapid mo-The cloned env sequences conferred distinct replica-
tion kinetics on the NL4-3/env recombinant viruses (Ta- bility than full-length Env (gp160) and a gp120 form (the
SU subunit of gp160).ble 1). Replication studies were initiated by cocultivating
COS cells transiently transfected with the recombinant The total levels of expression of the vaccine plasmids
in transiently transfected COS cells were fairly similarviruses with PBMCs. Within each patient series, trans-
fected COS cells showed less than a 2.5-fold variation (Table 2). With one exception, both forms of all Envs were
expressed at 12 to 62 ng per transfection. This level ofin the levels of the expression of the transfected virus or
a control cotransfected hGH plasmid (Table 1 and data expression was similar to that of the gp120 and gp140
forms of the T-cell-line-adapted HXB-2 Env. The one ex-not shown). In contrast, the cocultivations revealed
marked differences in the replication phenotypes of the ception, the gp120 form of 5B, was expressed at much
TABLE 1
Cytotropism and Syncytium Inducing Activity of NL4-3/Env Recombinants
Transfection Cytotropism: Syncytium
DNA efficiencya Expressionb PBMC MT-2 H9 A3.01 CEMx174 inductionc
pNL4-3/5A 18 10% (3.7) ///// //// // // / SI
pNL4-3/5B 31 15% (4.9) { 0 { 0 0 (NSI)
pNL4-3/5C 15 11% (2.6) { 0 { 0 0 (NSI)
pNL4-3/6A 10 7% (2.4) /// { { 0 0 NSI
pNL4-3/6B 6 8% (1.9) ///// ///// //// // ///// SI
pNL4-3/6C 10 15% (3.6) ///// ///// /// // // SI
pNL4-3/6D 14 9% (2.3) ///// ///// // / // SI
pNL4-3 parent 17 13% (4.2) ///// ///// ///// ///// ///// SI
a Nanogram of human growth hormone per milliliter of culture supernate at 72 hr posttransfection.
b Percentage of transfected COS cells scoring for virus proteins using an indirect immunofluorescence assay (relative units of HIV-1 proteins in
COS cell lysates). The assays were performed at 72 hr posttransfection.
c SI, syncytium induction; NSI, non-syncytium-inducing; (NSI) syncytium not observed; however, poor replication of the virus could have precluded
the formation of syncytia. Syncytia were scored according to Koot et al. (1992).
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FIG. 4. Example of Western blot analyses of pJW4303-expressed
gp120 and gp140. The Envs under analysis are indicated at the tops
of the gels and sizes of the marker HXB-2 gp160 Env on the sides. All
envs were expressed in transiently transfected COS cells.
lower levels of 2 ng per transfection. In these transfec-
tions, the cotransfected hGH plasmid was expressed at
similar levels to those observed in transfections with the
other vaccine plasmids (118 to 282 ng per transfection).
This suggested that the low level of expression of the
5B gp120 was specific to sequences in this construct.
FIG. 5. Analysis of the ability of the gp120 and gp140 forms of the
The extent of secretion of the gp120 and gp140 pro- patient 5 Envs to raise antibody in NZW rabbits. Gene gun DNA immuni-
teins was assessed in COS cells by using an antigen zations are indicated as dotted lines. Symbols used for rabbits follow:
5A gp120, R41(s), R42(h); 5B gp120, R28(s), R29(h), R30(n); 5B gp120,capture ELISA to quantitate Env in cell lysates and cul-
R43(s), R44(h), R45(n); 5B gp140, R61(s), R62(h), R88(n).ture medium. These analyses revealed that the gp120
forms of all of the Envs were efficiently secreted. Be-
tween 92 and 95% of the total gp120 was found in the ciently secreted. Only 18 to 60% of these proteins were
culture medium (Table 2). The gp140s were less effi- present in culture medium (Table 2).
Despite the fairly similar levels of expression in trans-
fected COS cells, the DNA-expressed Envs differed in
TABLE 2 their abilities to raise antibody in rabbits (Table 2, Figs.
Expression and Immunogenicity of Patient Envs 5 and 6). Multiple DNA immunizations of all of the Envs
were required to elicit antibody (Figs. 5 and 6). In in-
Expression, ng stances where antibody was raised, titers generally
(percentage secreted)a Anti-Env IgG, mg/mlb
peaked at 2 weeks postboost and declined by 8 weeks
postboost. Both peaks and troughs of antibody titers roseEnv gp120 gp140 gp120 gp140
with sequential immunizations. As the number of immuni-
HXB-2 12 (92%) 15 (50%) 6.3 3.3 zations increased, there tended to be less than a 10-fold
5.7 1.6 difference between peaks and troughs.
5A 62 (93%) 37 (60%) 8.6 0.6
A number of gene gun delivery conditions were used0.2 0.5
over the course of the experiment (see Materials and0.2
5B 2 (94%) 12 (27%) 4.6 0.3 Methods). These differences in conditions did not corre-
4.3  late with immunogenicity or antibody titers (see rabbits
2.8  with identical spacings of DNA deliveries, Figs. 5 and 6).
6A 42 (93%) 43 (30%) 1.0 0.3
Thus, the multiple boosts appeared to have evened out 
potential differences in efficiency of the different immuni- 
6C 16 (94%) 24 (18%)   zation conditions.
  As a whole, the primary gp120s raised higher titers of
6D 44 (95%) 25 (27%)   antibody than the primary gp140s (Table 2). Within the 
gp120s, the patient 5 gp120s were more immunogenic 
than the patient 6 gp120s (Table 2). The patient 5 gp120s
a Numbers are nanograms of Env per transfection. Secreted protein raised antibody in each of five immunized rabbits
is represented as the percentage of the total expressed protein present whereas the patient 6 gp120s raised antibody in only
in the culture medium. The transfection efficiency was monitored using one of eight immunized rabbits. Peak anti-Env titers for
human growth hormone which ranged from 114 to 282 ng per transfec-
the patient 5 gp120s ranged from 0.2 to 8.6 mg of specifiction.
IgG per milliliter, whereas the one seroconverter for pa-b Numbers are peak titers for individual rabbits, listed from the high-
est to the lowest responder for each group. tient 6 gp120s had a peak titer of 1 mg of specific IgG
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gp140 form of HXB-2 raised lower titers of antibody than
the gp120 form. However, these titers were ‘‘high’’ (1.6
and 3.3 mg/ml) when compared with those raised by
patient gp140s (£0.6 mg/ml) (Table 2).
DISCUSSION
Our data demonstrate that the immunogenicity of
gp120 and gp140 forms of Env from primary isolates
correlates with the patient from which the Env was
cloned and not the cytotropism or syncytium-inducing
potential of the Env (Tables 1 and 2). For all of the
Envs, the gp120 form was more immunogenic than the
corresponding gp140 form (Table 2). The gp120 forms
of the patient 5 primary Envs were as immunogenic as
the gp120 form of HXB-2, a T-cell line-adapted Env
(Table 2). In contrast, the gp140 forms of the primary
Envs were less immunogenic than the gp140 form of
HXB-2 (Table 2).
Influence of source and form of Env on immunogenic
potential
Within the two series of primary Envs, the source (pa-
tient 5 or patient 6) and the form (gp120 versus gp140)
of the Env had the most effect on the ability to raise
antibody (Table 2 and Figs. 5 and 6). The gp120 forms
of patient 5, but not patient 6 Envs, had good immunoge-
nicity. With the exception of one low responding rabbit
FIG. 6. Analysis of the ability of the gp120 and gp140 forms of the immunized with the 5A gp120, antibody titers elicited by
patient 6 Envs to raise antibody in NZW rabbits. Gene gun DNA immuni- the gp140 forms of both patient 5 and 6 Envs were lower
zations are indicated as dotted lines. Symbols used for rabbits follow:
than the corresponding gp120s. These results suggest6A gp120, R46(s), R47(h), R48(n); 6A gp140, R31(s), R32(h), R33(n);
that immunodominant epitopes on both patient 5 and 66C gp120, R49(s), R51(h); 6C gp140, R64(s), R65(h), R66(n); 6D
Envs were exposed on the monomeric gp120 form, butgp120, R52(s), R53(h), R75(n); 6D gp140, R34(s), R35(h), R36(n).
sequestered on the gp140 form that is likely to be oligo-
meric (see Moore and Sodroski, 1996; for reviews, see
Moore and Ho, 1995; Kent and Robinson, 1996). Theseper milliliter. The low level of expression of the 5B gp120
in COS cells did not appear to limit its immunogenicity results also suggest that the immunogenicity of the
‘‘oligomer-masked’’ epitopes on the patient 5 and patient(Tables 1 and 2).
For both patients, the gp140 forms of Env were less 6 gp120s were not related to the replication phenotypes
of these Envs (Table 1).immunogenic than the corresponding gp120 forms (Ta-
ble 2). In the patient 5 series, this was reflected in both The immunogenicities of the patient gp120s over-
lapped that of the T-cell line-adapted HXB-2 gp120. Inlower frequencies of seroconversion (four of six rabbits
immunized with gp140-expressing plasmids as opposed contrast, the immunogenicities of the patient gp140s
were consistently lower than that of the HXB-2 gp140.to five of five rabbits immunized with gp120-expressing
plasmids), and lower titers of antibody in rabbits that did The HXB2 gp140 may be more immunogenic because of
the inherent instability of Env spikes from T-cell line-seroconvert (up to 0.6 mg/ml for gp140 versus up to 8.6
mg/ml for gp120) (Table 2). For the less immunogenic adapted viruses. Indeed T-cell-line-adapted strains of
HIV-1 are known to shed monomeric gp120 more easilypatient 6 Envs, only one of nine rabbits immunized with
plasmids expressing the gp140 form seroconverted. This than primary isolates (for review see Moore and Ho,
1995). This instability would lead to exposure of the epi-rabbit developed a lower titer (0.3 mg/ml) than the one
rabbit seroconverting with the gp120 plasmid (1.0 mg/ml) topes on gp140 that are masked in the oligomer causing
the antigenicity of HXB-2 gp140 to approach that of HXB-(Table 2).
The most distinctive difference in the immunogenicity 2 gp120.
All of the ELISAs in this study used a IIIb-Env as theof the primary Envs and the HXB-2-T-cell-line-adapted
Env was the relatively high immunogenicity of the gp140 solid-phase antigen. This common Env could have bi-
ased our results by failing to detect type-specific determi-form of HXB-2 (Table 2). As with the patient Envs, the
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nants in the patients 5 and 6 series. However, we con- and 6D Envs (all ‘‘rapid/high’’), amply demonstrate that
the ‘‘rapid/high’’ phenotype does not necessarily makesider a strong bias unlikely as HIV-1 Envs (even those
from different clades) cross-react in binding assays an Env immunogenic.
(Moore et al., 1996). Attempts to use FACS analyses of
Low immunogenic potential of Envinfected cells to titer rabbit sera revealed that the titers
of anti-Env IgG were below the threshold of detection for
The DNA-mediated immunizations with the primarythis assay.
Envs, as well as the T-cell line-adapted HXB-2 Env, elic-
ited quite low titers of anti-Env IgG (Figs. 5 and 6, TableLack of correlation between the growth potential and
2). This low immunogenicity is likely to be related to thethe immunogenic potential of patient Envs
highly glycosylated nature of the HIV-1 Env (Leonard et
One of the hypotheses behind this study was that the al., 1990; Myers et al., 1994). HIV-1 Envs have as many
replication phenotype of an Env would influence the im- as 25–30 N-linked glycosylation sites on each monomer
munogenicity of the Env. ‘‘Slow/low’’ Envs may sequester (75 glycosylation sites per oligomer). This level of gly-
epitopes needed for entry; a sequestration that could cosylation is 5 to 6 times higher than that for the influenza
affect in turn the ability of these Envs to raise neutralizing and measles hemagglutinin glycoproteins. Single DNA
antibody. immunizations with these hemagglutinins can raise con-
Interestingly, marked differences in replication poten- valescent titers of neutralizing antibody (Robinson et al.,
tial and syncytium-inducing potential did not influence 1995; Yang et al., in press). Thus the immunodeficiency
the immunogenicity of the patient 5 and 6 Envs (Tables viruses, which maintain chronic infections by continuous
1 and 2). Within the patient 5 and 6 series, the Envs that replication in the face of strong immune responses (Ho
supported rapid replication were no more immunogenic et al., 1995; Wei et al., 1995), may have been selected for
than the Envs that supported low replication. This sug- highly glycosylated envelope glycoproteins that minimize
gests that conformational changes which expose epi- the immunogenicity of viral particles.
topes involved in CD4 binding and fusion, do not affect This study, as well as less extensive prior studies us-
overall immunogenicity. Assays for neutralizing activity ing DNA to raise antibody to HIV-1 Envs (Wang et al.,
have also not revealed a correlation between replication 1993a; 1993b; Fuller and Haynes, 1994; Lu et al., 1995;
potential and the ability to raise neutralizing antibody Okuda et al., 1995), amply demonstrate that DNA-based
(manuscript in preparation). immunizations do not overcome the low immunogenicity
of immunodeficiency envelope glycoproteins. The chal-
Role of Env in replication phenotypes lenge for future studies will be to develop constructs and
protocols that can overcome this low immunogenicity.The NL4-3/env recombinants exhibited a spectrum of
replication potentials, cytotropisms and abilities to in-
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